CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

176 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DPIK3CAC420RPredictiveSupportsResistanceHer2-receptor Positive Breast CancerTrastuzumabBaselga et al., 2016
DPIK3CAK111NPredictiveDoes Not SupportResistanceHer2-receptor Positive Breast CancerTrastuzumabBaselga et al., 2016
DPIK3CAI391MPredictiveDoes Not SupportResistanceHer2-receptor Positive Breast CancerTrastuzumabBaselga et al., 2016
DPIK3CAC604RFunctionalSupportsGain of FunctionNg et al., 2018
DPIK3CAD350NFunctionalSupportsGain of FunctionNg et al., 2018
DPIK3CAG1007RFunctionalSupportsGain of FunctionNg et al., 2018
DPIK3CAN1044KFunctionalSupportsGain of FunctionNg et al., 2018
APIK3CAR88QPredictiveSupportsSensitivity/ResponseHer2-receptor Negative Breast CancerFulvestrant,CapivasertibTurner et al., 2023
DPIK3CAH1047RPredictiveSupportsSensitivity/ResponseHead And Neck CancerDactolisibWirtz et al., 2015
DPIK3CAH1047RPredictiveSupportsSensitivity/ResponseHead And Neck CancerAlpelisibKeam et al., 2015
DPIK3CAAmplificationPredictiveSupportsSensitivity/ResponseHead And Neck Squamous Cell CarcinomaTaselisibZumsteg et al., 2016
CPIK3CAE545KPredictiveSupportsSensitivity/ResponseCancerApitolisibDolly et al., 2016
DPIK3CAMutationPredictiveSupportsResistanceColorectal CancerCetuximabBertotti et al., 2011
DPIK3CAE542KPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPI-103O'Brien et al., 2010
BPIK3CAH1047R OR PIK3CA H1047LPrognosticSupportsPoor OutcomeBreast Tubular CarcinomaCheng et al., 2017
CPIK3CAN345KPredictiveSupportsResistanceColorectal CancerCetuximabDe Roock et al., 2010
DPIK3CAE542KPredictiveSupportsResistanceBreast CancerPI-103O'Brien et al., 2010
DPIK3CAE545KPredictiveSupportsResistanceBreast CancerPI-103O'Brien et al., 2010
DPIK3CAH1047LPredictiveSupportsSensitivity/ResponseBreast CancerPI-103O'Brien et al., 2010
DPIK3CAK111NPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPI-103O'Brien et al., 2010
DPIK3CAE542KPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPI3Ka/DiO'Brien et al., 2010
DPIK3CAE542KPredictiveSupportsSensitivity/ResponseBreast CancerPI3Ka/DiO'Brien et al., 2010
DPIK3CAE545KPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPI3Ka/DiO'Brien et al., 2010
DPIK3CAE545KPredictiveSupportsSensitivity/ResponseBreast CancerPI3Ka/DiO'Brien et al., 2010
DPIK3CAH1047LPredictiveSupportsSensitivity/ResponseBreast CancerPI3Ka/DiO'Brien et al., 2010
DPIK3CAK111NPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPI3Ka/DiO'Brien et al., 2010
Page 4 of 4
Previous